Featured Research

from universities, journals, and other organizations

BRCA1 gene mutation associated with neoadjuvant chemotherapy

Date:
September 6, 2011
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) -- the disappearance of all evidence of disease from the breast tissue and lymph nodes -- regardless of disease stage after standard neoadjuvent chemotherapy, according to new research.

Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) -- the disappearance of all evidence of disease from the breast tissue and lymph nodes -- regardless of disease stage after standard neoadjuvent chemotherapy, according to new research from The University of Texas MD Anderson Cancer Center.

The study, published online in The Journal of Clinical Oncology on September 6, is the largest study to date to find that the pCR rate is significantly higher in BRCA1 carriers (46 percent) than in women carrying the BRCA2 mutation (13 percent) and non-carriers (22 percent). Among all the women, researchers did not find a statistical difference in overall survival rates, but noted that BRCA1 carriers who achieved a pCR had better five-year, relapse-free survival and overall survival rates.

BRCA1 and BRCA2 belong to a class of human genes known as tumor suppressors. The mutation is inherited and increases a woman's chance of developing breast cancer with more aggressive features by 80 percent. Researchers aimed to determine whether women with and without the mutations would respond differently to the same treatment.

"While hereditary breast cancers typically carry aggressive tumor features compared to sporadic breast cancers, we found that BRCA1-related tumors were as responsive and sensitive to anthracycline and taxane-based chemotherapy as were sporadic breast cancers," said Banu Arun, M.D., professor in the Department of Breast Medical Oncology at MD Anderson and lead author of the study. "These findings may help physicians determine the best treatment method for this subset of women with unique genetic mutations."

For the study, researchers used MD Anderson's Breast Cancer Management System Database to identify 317 women at varying disease stages who received neoadjuvent chemotherapy and clinical genetic testing for BRCA1 and BRCA2 between 1997 and 2009. Fifty- seven women were BRCA1 carriers, 23 were BRCA2 mutation carriers and 237 were non-carriers. After chemotherapy, 61 patients received breast-conserving surgery, while 256 opted for mastectomy.

Median follow up time for the patients was 3.2 years, at which point 22 percent of patients experienced disease recurrence or death. There were no significant differences noted in survival outcomes with respect to BRCA status and type of neoadjuvent chemotherapy received.

According to Arun, there is no consensus on the most effective chemotherapy regimen for treating women who carry the BRCA mutation, due to a lack of prospective studies.

"This new insight tempts us to speculate that the presence of the BRCA1 mutation determines how some women will respond to neoadjuvent chemotherapy. However, we need future prospective studies with larger cohorts and longer-term follow up to validate these findings and determine optimum treatment," Arun noted.

Additional researchers on the all-MD Anderson study from the Department of Breast Medical Oncology include: Angelica M. Gutierrez Barrera, M.S., Deann Atchley, Ph.D, Lajos Pusztai, M.D., Jennifer Litton, M.D., Vicente Valero, M.D., and Gabriel N. Hortobagyi, M.D. Also contributing were Soley Bayraktar, M.D., Department of Cancer Medicine; Diane Liu, M.S., Department of Biostatistics; Funda Meric-Bernstam, M.D., Department of Surgical Oncology; and Constance Albarracin, M.D., Department of Pathology.

The study was partially funded by the Lynn Cohen Breast and Ovarian Cancer Project and the Nellie B. Connally Breast Cancer Research Fund.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Banu Arun, Soley Bayraktar, Diane D. Liu, Angelica M. Gutierrez Barrera, Deann Atchley, Lajos Pusztai, Jennifer Keating Litton, Vicente Valero, Funda Meric-Bernstam, Gabriel N. Hortobagyi, and Constance Albarracin. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. JCO, Sep 6, 2011 DOI: 10.1200/JCO.2011.35.2682

Cite This Page:

University of Texas M. D. Anderson Cancer Center. "BRCA1 gene mutation associated with neoadjuvant chemotherapy." ScienceDaily. ScienceDaily, 6 September 2011. <www.sciencedaily.com/releases/2011/09/110906161622.htm>.
University of Texas M. D. Anderson Cancer Center. (2011, September 6). BRCA1 gene mutation associated with neoadjuvant chemotherapy. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2011/09/110906161622.htm
University of Texas M. D. Anderson Cancer Center. "BRCA1 gene mutation associated with neoadjuvant chemotherapy." ScienceDaily. www.sciencedaily.com/releases/2011/09/110906161622.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins